Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients

Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients

Source: 
Fierce Pharma
snippet: 

While the FDA has been monitoring the impact of the COVID-19 outbreak on drug supplies to the U.S., it turns out the Trump administration's ban on travel from Europe threatened to interrupt shipments of Novartis’ Kymriah gene therapy, delivery of which is time-sensitive.